As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
7 Analysts have issued a Cue Biopharma, Inc. forecast:
7 Analysts have issued a Cue Biopharma, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 7.10 7.10 |
25%
25%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -38 -38 |
17%
17%
|
|
| EBIT (Operating Income) EBIT | -38 -38 |
17%
17%
|
|
| Net Profit | -38 -38 |
16%
16%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Daniel Passeri |
| Employees | 41 |
| Founded | 2014 |
| Website | www.cuebiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


